NextCure Hopes Its Novel Target Therapies Will Treat Patients Not Helped By PD-1/L1 Inhibition

Emerging Company Profile: Based on discovery research at Yale, NextCure hopes S15 and other novel targets will provide new inroads in immuno-oncology, while much of the field remains focused on PD-1 inhibitors and combinations.